CN103667267B - 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 - Google Patents
用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 Download PDFInfo
- Publication number
- CN103667267B CN103667267B CN201310429758.2A CN201310429758A CN103667267B CN 103667267 B CN103667267 B CN 103667267B CN 201310429758 A CN201310429758 A CN 201310429758A CN 103667267 B CN103667267 B CN 103667267B
- Authority
- CN
- China
- Prior art keywords
- dna
- seq
- storehouse
- dna probe
- kras gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150105104 Kras gene Proteins 0.000 title claims abstract description 83
- 239000012634 fragment Substances 0.000 title claims abstract description 61
- 239000003298 DNA probe Substances 0.000 title claims abstract description 53
- 108020003215 DNA Probes Proteins 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000006798 recombination Effects 0.000 title claims abstract description 13
- 238000005215 recombination Methods 0.000 title claims abstract description 13
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims description 158
- 239000002299 complementary DNA Substances 0.000 claims description 59
- 238000013467 fragmentation Methods 0.000 claims description 29
- 238000006062 fragmentation reaction Methods 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 25
- 238000012408 PCR amplification Methods 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 9
- 239000011735 vitamin B7 Substances 0.000 claims description 8
- 229930003756 Vitamin B7 Natural products 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 235000011912 vitamin B7 Nutrition 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 39
- 238000005516 engineering process Methods 0.000 abstract description 38
- 238000012163 sequencing technique Methods 0.000 abstract description 31
- 230000035772 mutation Effects 0.000 abstract description 27
- 238000001514 detection method Methods 0.000 abstract description 19
- 230000008859 change Effects 0.000 abstract description 15
- 230000008034 disappearance Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 115
- 238000000746 purification Methods 0.000 description 32
- 239000011324 bead Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000006148 magnetic separator Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000013016 damping Methods 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 101710163270 Nuclease Proteins 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 102100030708 GTPase KRas Human genes 0.000 description 9
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 9
- 108010090804 Streptavidin Proteins 0.000 description 9
- 230000001186 cumulative effect Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000000137 annealing Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 206010064571 Gene mutation Diseases 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 230000031700 light absorption Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000004451 qualitative analysis Methods 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- HDVCHBLHEICPPP-UHFFFAOYSA-N O=P(=O)C1=CC=NC(P(=O)=O)=C1P(=O)=O Chemical class O=P(=O)C1=CC=NC(P(=O)=O)=C1P(=O)=O HDVCHBLHEICPPP-UHFFFAOYSA-N 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
反应材料 | 体积 |
纯化后cDNA/DNA样本库 | 50微升 |
磷酸化反应缓冲液 | 10微升 |
脱氧碱基混合物dNTP(每种lOmM) | 4微升 |
T4DNA聚合酶 | 5微升 |
Klenow大肠杆菌聚合酶片段 | 1微升 |
T4多聚核苷酸激酶 | 5微升 |
无核酸酶水 | 总体积补至100微升 |
反应材料 | 体积 |
cDNA/DNA样本库 | 约30微升 |
1OXKlenow大肠杆菌聚合酶缓冲液 | 5微升 |
脱氧碱基dATP(1mM) | 10微升 |
Klenow大肠杆菌聚合酶片段 | 3微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
cDNA/DNA样本库 | 约15微升 |
2XT4DNA连接酶缓冲液 | 5微升 |
DNA两端接头 | 6微升 |
T4DNA连接酶 | 3微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
加上接头后的cDNA/DNA样本库 | 约30微升 |
lOX高准确率超保真DNA聚合酶缓 | 5微升 |
冲液 | |
高准确率超保真DNA聚合酶 | 1微升 |
接头正引物 | 1微升 |
接头反引物 | 1微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
富集cDNA/DNA样本库 | 约30微升 |
lOX高准确率超保真DNA聚合酶缓冲液 | 5微升 |
高准确率超保真DNA聚合酶 | 1微升 |
正引物 | 1微升 |
反引物 | 1微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
纯化后cDNA/DNA样本库 | 50微升 |
磷酸化反应缓冲液 | 10微升 |
脱氧碱基混合物dNTP(每种1OmM) | 4微升 |
T4DNA聚合酶 | 5微升 |
Klenow大肠杆菌聚合酶片段 | 1微升 |
T4多聚核苦酸激酶 | 5微升 |
无核酸酶水 | 总体积补至100微升 |
反应材料 | 体积 |
cDNA/DNA样本库 | 约30微升 |
1OXKlenow大肠杆菌聚合酶缓冲液 | 5微升 |
脱氧碱基dATP(1mM) | 10微升 |
Klenow大肠杆菌聚合酶片段 | 3微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
cDNA/DNA样本库 | 约15微升 |
2XT4DNA连接酶缓冲液 | 5微升 |
DNA两端接头 | 6微升 |
T4DNA连接酶 | 3微升 |
无核酸酶水 | 总体积补至50微升 |
反应材料 | 体积 |
富集cDNA/DNA样本库 | 约30微升 |
lOX高准确率超保真DNA聚合酶缓冲液 | 5微升 |
高准确率超保真DNA聚合酶 | 1微升 |
正引物 | 1微升 |
反引物 | 1微升 |
无核酸酶水 | 总体积补至50微升 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310429758.2A CN103667267B (zh) | 2012-09-18 | 2013-09-18 | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210346971 | 2012-09-18 | ||
CN2012103469712 | 2012-09-18 | ||
CN201210346971.2 | 2012-09-18 | ||
CN201310429758.2A CN103667267B (zh) | 2012-09-18 | 2013-09-18 | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103667267A CN103667267A (zh) | 2014-03-26 |
CN103667267B true CN103667267B (zh) | 2015-09-30 |
Family
ID=50306040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310429758.2A Active CN103667267B (zh) | 2012-09-18 | 2013-09-18 | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103667267B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106520963B (zh) * | 2016-11-18 | 2019-12-17 | 上海思路迪生物医学科技有限公司 | 高通量测序检测人循环肿瘤dna kras基因的捕获探针及试剂盒 |
CN106834515B (zh) * | 2017-02-22 | 2018-05-04 | 南京世和基因生物技术有限公司 | 一种检测met基因14外显子突变的探针库、检测方法和试剂盒 |
CN107502654A (zh) * | 2017-06-15 | 2017-12-22 | 至本医疗科技(上海)有限公司 | 用于实体瘤靶向用药指导的多基因富集和检测方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101899496A (zh) * | 2009-05-27 | 2010-12-01 | 广州达健生物科技有限公司 | 一种K-Ras基因突变分型荧光定量PCR检测试剂盒及其检测方法 |
CN102010894B (zh) * | 2010-03-09 | 2013-04-24 | 上海源奇生物医药科技有限公司 | 检测人K-ras基因外显子12、13突变的核苷酸序列、方法及试剂盒 |
CN102344961B (zh) * | 2011-09-30 | 2015-12-09 | 北京康旭医学检验所有限公司 | 一种经济的应用大规模平行测序技术检验多目标多基因的方法 |
-
2013
- 2013-09-18 CN CN201310429758.2A patent/CN103667267B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103667267A (zh) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475375B (zh) | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 | |
CN106834515B (zh) | 一种检测met基因14外显子突变的探针库、检测方法和试剂盒 | |
CN105506746A (zh) | 构建可变区测序文库的方法及确定可变区核酸序列的方法 | |
CN104745679A (zh) | 一种无创检测egfr基因突变的方法及试剂盒 | |
CN107849606A (zh) | 提高下一代测序灵敏度的方法 | |
CN104350161A (zh) | 用于核酸分子中的敏感突变检测的组合物和方法 | |
CN104450885A (zh) | 一种检测神经纤维瘤病相关基因突变的试剂盒 | |
CN110741096B (zh) | 用于检测循环肿瘤dna的组合物和方法 | |
KR20180098412A (ko) | 종양의 심층 서열분석 프로파일링 | |
CN106048008A (zh) | 一种egfr基因超低频突变检测试剂盒 | |
CN103667269B (zh) | 用于与bcr或abl基因杂交的dna探针库及采用其富集bcr-abl基因片段的方法 | |
CN105793438A (zh) | 未知序列的双股线性核酸的全长扩增方法 | |
CN113557300A (zh) | 核酸序列、rna目标区域测序文库的构建方法及应用 | |
CN111690748B (zh) | 使用高通量测序检测微卫星不稳定的探针组、试剂盒及微卫星不稳定的检测方法 | |
CN103667267B (zh) | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 | |
CN106350586A (zh) | 确定噬血细胞综合征的基因突变位点的方法 | |
CN105473736A (zh) | 基于纳米探针的遗传学检验 | |
CN103667268B (zh) | 用于与braf基因杂交的dna探针库及采用其富集braf基因片段的方法 | |
CN103911439A (zh) | 系统性红斑狼疮羟甲基化状态的差异表达基因的分析方法和应用 | |
CN108624686B (zh) | 一种检测brca1/2突变的探针库、检测方法和试剂盒 | |
CN103667270B (zh) | 用于与egfr基因杂交的dna探针库及采用其富集egfr基因片段的方法 | |
CN102827935B (zh) | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 | |
CN109762901B (zh) | 用于富集低频dna突变的dna探针应用于多种突变的同时检测 | |
CA3151627A1 (en) | Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment | |
CN112359116A (zh) | 一种检测dna跨损伤合成修复通路关键突变基因的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GENESEEQ TECHNOLOGY INC. Free format text: FORMER OWNER: SHAO YANG Effective date: 20140903 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 333100 SHANGRAO, JIANGXI PROVINCE TO: 210061 NANJING, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140903 Address after: 210061, building 609, block A, Spark Road, No. 10, Spark Road, hi tech Zone, Jiangsu, Nanjing Applicant after: GENESEEQ TECHNOLOGY Inc. Address before: 333100 Jiangxi city of Shangrao province Poyang County Poyang Zhenkang Fu Lu No. 8 Applicant before: Shao Yang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: Nanjing and the medical equipment Co., Ltd. Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2016320000197 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20161019 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: Nanjing hi tech precision medical science and Technology Co Ltd Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000151 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170613 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: Liu Yichuan Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000166 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170814 Application publication date: 20140326 Assignee: Wu Xue Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000168 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170814 Application publication date: 20140326 Assignee: Xia Yewei Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000167 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170814 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: Liu Sisi Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000172 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170817 Application publication date: 20140326 Assignee: Zhu Mingfu Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000171 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170817 Application publication date: 20140326 Assignee: Na Chenglong Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000173 Denomination of invention: DNA (Deoxyribonucleic Acid) probe library used for hybridization with KRAS gene and method for enriching KRAS gene segments by adopting DNAprobe library Granted publication date: 20150930 License type: Common License Record date: 20170817 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Zhu Ming Fu Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000171 Date of cancellation: 20191015 Assignee: Liu Yi Chuan Assignor: GENESEEQ TECHNOLOGY Inc. Contract record no.: 2017320000166 Date of cancellation: 20191015 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 210061, building 609, block A, Spark Road, No. 10, Spark Road, hi tech Zone, Jiangsu, Nanjing Patentee after: Nanjing Shihe gene Biotechnology Co., Ltd Address before: 210061, building 609, block A, Spark Road, No. 10, Spark Road, hi tech Zone, Jiangsu, Nanjing Patentee before: GENESEEQ TECHNOLOGY Inc. |
|
CP01 | Change in the name or title of a patent holder |